Preclinical studies also highlight the potential of multi-target agents, like ZLY18 (a quadruple FFA1/PPAR-α/γ/δ agonist), which significantly improved liver histology in NASH models, warranting further investigation [255]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.